Literature DB >> 8544903

Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe.

W E Klunk1, M L Debnath, J W Pettegrew.   

Abstract

Chrysamine-G (CG) is a carboxylic acid analogue of Congo red, a histologic dye which stains amyloid. CG binds to the beta-amyloid protein of Alzheimer's disease (AD) in vitro and partitions into the brain of normal mice. In this study, we demonstrate increased binding of [14C]CG to homogenates of several regions of AD brain as compared to control. The total binding of CG to AD brain was approximately two- to three-fold that of control brain. The cerebellum could be used as an internal standard for each brain as CG binding to cerebellum did not differ between AD and control. The binding of [14C]CG correlated with numbers of senile plaques and neurofibrillary tangles. In addition, CG could be used to stain cerebrovascular amyloid in tissue sections. These results suggest that CG may prove useful as an in vivo probe of amyloid deposition in AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8544903     DOI: 10.1016/0197-4580(95)00058-m

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  21 in total

Review 1.  In vivo amyloid imaging in Alzheimer's disease.

Authors:  H I Sair; P M Doraiswamy; J R Petrella
Journal:  Neuroradiology       Date:  2004-01-23       Impact factor: 2.804

Review 2.  In vivo brain imaging of tangle burden in humans.

Authors:  Gary W Small; Eric D Agdeppa; Vladimir Kepe; Nagichettiar Satyamurthy; Sung-Cheng Huang; Jorge R Barrio
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

3.  Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein.

Authors:  M Soledad Celej; Elizabeth A Jares-Erijman; Thomas M Jovin
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

4.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

5.  Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation.

Authors:  Elisa A Waxman; Kristel L Emmer; Benoit I Giasson
Journal:  Biochem Biophys Res Commun       Date:  2009-12-21       Impact factor: 3.575

Review 6.  Development of positron emission tomography β-amyloid plaque imaging agents.

Authors:  Chester A Mathis; N Scott Mason; Brian J Lopresti; William E Klunk
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

Review 7.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

8.  The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains.

Authors:  M L Schmidt; T Schuck; S Sheridan; M P Kung; H Kung; Z P Zhuang; C Bergeron; J S Lamarche; D Skovronsky; B I Giasson; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

9.  Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.

Authors:  Mei-Ping Kung; Daniel M Skovronsky; Catherine Hou; Zhi-Ping Zhuang; Tamar L Gur; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee; Hank F Kung
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

10.  Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status.

Authors:  Minna Groenning
Journal:  J Chem Biol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.